Navigation Links
Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune

CARLSBAD, Calif., April 23, 2007 /PRNewswire-FirstCall/ Micromet, Inc. today announced the achievement of a milestone in its research collaboration with MedImmune, Inc. for the development of new BiTE(R) molecules targeting carcinoembryonal antigen (CEA), a validated tumor- associated antigen frequently expressed on various human carcinomas. Preclinical data recently presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) showed that CEA-BiTE molecules can prevent subcutaneous tumor growth and formation of lung metastases. Achievement of the preclinical proof-of-concept milestone in the CEA-BiTE program triggers an undisclosed payment from MedImmune to Micromet.

Micromet holds exclusive European rights to the CEA-BiTE program and is eligible for milestones and royalties for all other territories, including the U.S. Under the same agreement, both companies also collaborate on a new BiTE candidate targeting the tyrosine kinase receptor EphA2, which is frequently overexpressed on a wide variety of solid tumors.

"The achievement of this milestone further validates the versatility and power of the BiTE approach to treat various cancers by targeting different tumor antigens," said Patrick Baeuerle, Ph.D., Chief Scientific Officer of Micromet. "Following this initial success with the CEA-BiTE program, we are now advancing the second BiTE program through formal development with our partner MedImmune."

About BiTE(R) Molecules:

BiTE(R) molecules are a novel class of antibody derivatives with the potential to selectively direct and activate an individual's cytotoxic T cells, the body's most potent killer cells, to act against cancer cells. MT103/MEDI-538, a BiTE molecule targeting the B cell antigen CD19, provided clinical proof-of-concept for the BiTE platform technology, as presented at the most recent meeting of the American Society for Hematology. In an o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
2. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
4. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
5. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:10/30/2014)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... for cells and tissues, today announced today that ... released on Thursday, November 6, 2014, and that the ... at 1:30 p.m. PST that afternoon. Management will provide ...
(Date:10/30/2014)... 30, 2014 , Extensively hydrolyzed ... milk   Cow milk protein allergy (CMPA) is the leading ... Until now, it has been managed by eliminating milk ... shown that it is possible to help build of ... of children during the first year of life by ...
(Date:10/30/2014)... LONDON , Oct. 29, 2014 ... electrical potential which can be amplified to diagnose ... The electrodes used in medical devices facilitate the ... obtained from muscle cells and neurons of the ... electrodes utilize the radiofrequency alternating current to perform ...
Breaking Medicine Technology:BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4
... -- ShangPharma Corporation (NYSE: SHP ) ("ShangPharma" ... research and development outsourcing company, today announced that it ... in its biologics division, which portends strong growth for ... milestones were achieved for two oncology projects that are ...
... WuXi PharmaTech (Cayman) Inc. (NYSE: ... the pharmaceutical, biotechnology, and medical device industries, with operations in ... for the second quarter of 2011. Highlights ... Million for the First Time Second-Quarter 2011 Net ...
Cached Medicine Technology:ShangPharma's Biologics Division Announces Accelerated Achievement of Milestones for Two Multi-Stage Projects 2WuXi PharmaTech Announces Second Quarter 2011 Results 2WuXi PharmaTech Announces Second Quarter 2011 Results 3WuXi PharmaTech Announces Second Quarter 2011 Results 4WuXi PharmaTech Announces Second Quarter 2011 Results 5WuXi PharmaTech Announces Second Quarter 2011 Results 6WuXi PharmaTech Announces Second Quarter 2011 Results 7WuXi PharmaTech Announces Second Quarter 2011 Results 8WuXi PharmaTech Announces Second Quarter 2011 Results 9WuXi PharmaTech Announces Second Quarter 2011 Results 10WuXi PharmaTech Announces Second Quarter 2011 Results 11WuXi PharmaTech Announces Second Quarter 2011 Results 12WuXi PharmaTech Announces Second Quarter 2011 Results 13WuXi PharmaTech Announces Second Quarter 2011 Results 14WuXi PharmaTech Announces Second Quarter 2011 Results 15WuXi PharmaTech Announces Second Quarter 2011 Results 16WuXi PharmaTech Announces Second Quarter 2011 Results 17
(Date:10/30/2014)... October 30, 2014 Don Allred Insurance, ... health insurance plans for North Carolina residents, is excited ... in Burlington’s Holly Hill Mall. The new branch has ... already helping customers through all facets of the insurance ... Allred Insurance spokesman Scott Allred couldn’t be happier with ...
(Date:10/30/2014)... OR (PRWEB) October 30, 2014 Five ... firm Hodgkinson Street LLC announces new branding and ... Hodgkinson Street Mepham . After David Mepham’s promotion to ... their brand and website to include Mepham’s name and ... medical malpractice and mediation firm, the decision to implement ...
(Date:10/30/2014)... N.C. (PRWEB) October 30, 2014 Paramount ... health care, is increasing efforts to help people save ... expenses continue to increase for prescription drugs in the ... valuable savings and resources to bridge the relationship between ... One of the biggest challenges people face today with ...
(Date:10/30/2014)... Steven Reinberg HealthDay Reporter ... hormone therapy to men with prostate cancer who also have ... a heart-related cause, a new study suggests. , , The therapy ... in prostate cancer to reduce levels of male hormones to ... And, in the current research, this hormone therapy was linked ...
(Date:10/30/2014)... By Dennis Thompson ... -- The Ebola outbreak in Liberia -- one of three ... slowing, World Health Organization officials said Wednesday. Dr. Bruce ... in the number of burials in Liberia and no increase ... the global push to tame the epidemic may be making ...
Breaking Medicine News(10 mins):Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... study conducted by the University of Erfurt in Erfurt, ... inflict financial pain to achieve// collective gain. The study ... ,Researchers have found that groups in which individual ... popular than groups without this option. Though two thirds ...
... theme park people have come together to set up an ... from the Himalayan expedition to China and Nepal. They ... previously unknown to science. This was brought about by the ... a giant hornet which the local address as the Yak ...
... The drug Macugen was approved by the Food and ... as macular degeneration was reported// to show serious allergic ... use of their eye drug Macugen along with other ... companies have already notified the doctors about the reactions, ...
... a reassuring announcement that will bring hope to those people ... to be instituted, the government will realize its target of ... next two months. This will indeed provide a renewed thrust ... ,In the words of Anbumani Ramadoss “In another two ...
... Association (IMA),secretary of Ranchi, speaking for World Health ... all segments including doctors//, nurses, paramedics, laboratory technicians, ... society. ,The IMA secretary, Ajay Kumar ... healthcare, rather the cooperation of all healthcare segments ...
... with a new neupro skin patch which is offered the ... offer relief to patients// in the early stages of Parkinson's ... a naturally occurring brain chemical, which is in short supply ... said that the patch would aid the patients to manage ...
Cached Medicine News:Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 2Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 3Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 4Health News:Disney’s New Attraction Showcases the Discoveries of the Himalayas Expeditio 2Health News:Disney’s New Attraction Showcases the Discoveries of the Himalayas Expeditio 3Health News:Disney’s New Attraction Showcases the Discoveries of the Himalayas Expeditio 4
Anis tying forcep is extra delicate with smooth jaws, curved. For 9-0 to 11-0 sutures....
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches....
Straight shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Medicine Products: